Biogen
NEWS
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
Biogen successfully fended off a patent challenge from generic company Mylan over its multiple sclerosis (MS) drug Tecfidera.
Genentech’s Risdiplam showed significant improvement in motor function in people aged 2-25 who have been diagnosed with Type 2 or 3 spinal muscular atrophy.
In honor of Black History Month, BioSpace chose to highlight 10 African American leaders in the life sciences, individuals who have prominent roles in the life sciences and biopharmaceutical industry.
“In 2019 Biogen demonstrated strong execution across all of our core business areas with resilience in MS, continued strong worldwide growth for Spinraza, and an expanded biosimilars business,” noted Michel Vounatsos, Biogen’s chief executive officer.
Here’s a look at the top 10 companies noted in the BioSpace Ideal Employer 2019 survey for being the most innovative and what they’ve been up to recently.
What’s New at the J.P. Morgan Life Healthcare Conference?
The company has suggested that it plans to undercut both Biogen and Novartis on price in order to make up for being third-to-market.
Biogen is buying a novel CNS-penetrate inhibitor of casein kinase 1 (CK1) from Pfizer to develop for patients with behavioral and neurological symptoms in various psychiatric and neurologic diseases.
JOBS
IN THE PRESS